Details for Patent: 8,895,033
✉ Email this page to a colleague
Which drugs does patent 8,895,033 protect, and when does it expire?
Patent 8,895,033 protects BYDUREON BCISE and is included in one NDA.
Protection for BYDUREON BCISE has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.
This patent has thirty-one patent family members in twenty-three countries.
Summary for Patent: 8,895,033
Title: | Sustained release formulations using non-aqueous carriers |
Abstract: | The disclosure provides one-component, injectable, sustained release formulations which comprise microspheres containing active pharmaceutical ingredients (e.g., exenatide), wherein the microspheres are suspended in a non-aqueous carrier. The non-aqueous carrier can be an oil, a fractionated oil, triglycerides, diglycerides, monoglycerides, propylene glycol fatty acid diesters, and the like. The formulations offer distinct advantages of long shelf life for the stability and potency of the formulation and sustained release of active pharmaceutical ingredients to reduce the frequency of medication dosing and to increase patient compliance. |
Inventor(s): | Houchin; Mary L. (Rockville, MD), Lee; Robin H. (San Diego, CA), Qi; Hong (San Diego, CA), Oehrtman; Greg (San Diego, CA), Jennings; Robert N. (San Diego, CA), Coleman; Scott H. (San Diego, CA) |
Assignee: | Amylin Pharmaceuticals, LLC (San Diego, CA) AstraZeneca Pharmaceuticals LP (Wilmington, DE) |
Application Number: | 13/060,225 |
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Compound; Delivery; Device; Dosage form; |
Drugs Protected by US Patent 8,895,033
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Astrazeneca Ab | BYDUREON BCISE | exenatide synthetic | SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS | 209210-001 | Oct 20, 2017 | RX | Yes | Yes | ⤷ Try a Trial | ⤷ Try a Trial | Y | ⤷ Try a Trial | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
Foreign Priority and PCT Information for Patent: 8,895,033
PCT Information | |||
PCT Filed | September 04, 2009 | PCT Application Number: | PCT/US2009/056058 |
PCT Publication Date: | March 11, 2010 | PCT Publication Number: | WO2010/028257 |
International Family Members for US Patent 8,895,033
Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
---|---|---|---|---|---|
Australia | 2009289529 | ⤷ Try a Trial | |||
Brazil | PI0918904 | ⤷ Try a Trial | |||
Canada | 2734525 | ⤷ Try a Trial | |||
China | 102164597 | ⤷ Try a Trial | |||
China | 104248623 | ⤷ Try a Trial | |||
Cyprus | 1123410 | ⤷ Try a Trial | |||
>Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |